CRISPR Therapeutics (NASDAQ:CRSP) Price Target Increased to $52.00 by Analysts at Robert W. Baird

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) had its price target boosted by equities research analysts at Robert W. Baird from $46.00 to $52.00 in a report issued on Thursday, Benzinga reports. The firm presently has a "neutral" rating on the stock. Robert W. Baird's price objective would indicate a potential downside of 2.89% from the company's current price.

CRSP has been the subject of a number of other reports. Morgan Stanley raised their target price on CRISPR Therapeutics from $46.00 to $48.00 and gave the company an "underweight" rating in a research note on Monday, February 26th. TheStreet raised shares of CRISPR Therapeutics from a "d+" rating to a "c" rating in a research note on Friday, February 23rd. Mizuho increased their price target on shares of CRISPR Therapeutics from $82.00 to $99.00 and gave the company a "buy" rating in a research note on Wednesday, March 6th. Wells Fargo & Company upped their price objective on CRISPR Therapeutics from $55.00 to $70.00 and gave the stock an "equal weight" rating in a report on Thursday, February 22nd. Finally, Citigroup lifted their target price on CRISPR Therapeutics from $88.00 to $89.00 and gave the company a "buy" rating in a research note on Thursday, April 18th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, CRISPR Therapeutics currently has a consensus rating of "Hold" and an average price target of $73.73.

CRISPR Therapeutics Trading Up 0.5 %

Shares of CRISPR Therapeutics stock traded up $0.26 during mid-day trading on Thursday, reaching $53.55. 1,700,642 shares of the stock were exchanged, compared to its average volume of 1,760,389. The company has a market cap of $4.55 billion, a price-to-earnings ratio of -27.14 and a beta of 1.80. CRISPR Therapeutics has a fifty-two week low of $37.55 and a fifty-two week high of $91.10. The firm has a 50-day simple moving average of $65.81 and a 200 day simple moving average of $64.64.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its earnings results on Wednesday, May 8th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.35) by ($0.08). The firm had revenue of $0.50 million for the quarter, compared to the consensus estimate of $25.53 million. During the same period in the prior year, the business earned ($0.67) EPS. The company's revenue was down 99.5% compared to the same quarter last year. On average, research analysts predict that CRISPR Therapeutics will post -6.24 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Samarth Kulkarni sold 19,582 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $59.91, for a total value of $1,173,157.62. Following the sale, the chief executive officer now directly owns 208,122 shares in the company, valued at $12,468,589.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, General Counsel James R. Kasinger sold 2,801 shares of the company's stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $78.26, for a total transaction of $219,206.26. Following the sale, the general counsel now owns 60,070 shares in the company, valued at approximately $4,701,078.20. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Samarth Kulkarni sold 19,582 shares of the business's stock in a transaction on Monday, April 15th. The stock was sold at an average price of $59.91, for a total transaction of $1,173,157.62. Following the transaction, the chief executive officer now owns 208,122 shares in the company, valued at $12,468,589.02. The disclosure for this sale can be found here. In the last ninety days, insiders sold 83,992 shares of company stock valued at $6,132,335. Company insiders own 4.10% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Tradewinds Capital Management LLC grew its holdings in CRISPR Therapeutics by 545.5% during the third quarter. Tradewinds Capital Management LLC now owns 710 shares of the company's stock worth $32,000 after purchasing an additional 600 shares during the period. Blue Trust Inc. acquired a new position in shares of CRISPR Therapeutics during the 4th quarter worth approximately $32,000. Headlands Technologies LLC bought a new stake in CRISPR Therapeutics in the 3rd quarter valued at $34,000. Bourgeon Capital Management LLC lifted its holdings in CRISPR Therapeutics by 1,000.0% during the 4th quarter. Bourgeon Capital Management LLC now owns 550 shares of the company's stock valued at $34,000 after purchasing an additional 500 shares during the last quarter. Finally, Riggs Asset Managment Co. Inc. increased its holdings in shares of CRISPR Therapeutics by 66.7% in the first quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company's stock valued at $34,000 after purchasing an additional 200 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors and hedge funds.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.